Announcement PDF Emyria ASX Announcement | 11 December 2025 1 ASX RELEASE. 11 December 2025 Emyria Expands Perth Operations Ahead of Further National Clinical Growth Growing insurance-funded demand, rising AP approvals, increased capacity and a strengthened therapist capacity reinforce scalability Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) is pleased to report continued operational progress across its Perth Clinic network, supporting an expected increase in reimbursed clinical activity throughout 2026. AP approvals, therapist capability, clinical capacity and payer-funded pathways continue to strengthen, further validating the Perth operating model as a scalable template for the national Empax clinic rollout. Reimbursed Demand and Approvals Strengthening Reimbursed activity continues to grow through insurance-funded programs1,5,6 delivered at Emyria’s Perth Clinic and Avive Brisbane sites while newly established Department of Veterans’ Affairs (DVA)2 access pathways provide opportunities for veteran cohorts to also be treated at Emyria’s West Leederville community clinic. Strong Visibility into Early 2026 Activity Forward demand remains positive, with 67 initial screenings already scheduled for Q1 2026. These bookings provide clear visibility over near-term clinical activity, reinforcing predictable revenue across multiple reimbursement pathways for both community-based (West Leederville) and private-hospital–integrated (Perth Clinic3 and Avive Clinic4 ) care models. Clinician Capacity Expanded Perth AP approvals increased from 2 to 5, with 5 additional Perth applications advancing through the assessment pathway, reinforcing confidence in Emyria’s supervised, evidence- based care model. In addition, 39 Perth therapists are now trained and contracted to deliver Emyria’s Empax care protocol. This uplift supports the immediate patient pipeline and further demand anticipated across 2026. • Early 2026 Pipeline Increasing – 67 initial screenings for reimbursed treatments are currently booked for Q1 2026, demonstrating strong upcoming patient pipeline and driving capacity expansion in Perth and Brisbane. • Further Authorised Psychiatrist (AP) Approvals – Perth AP approvals have increased in number from 2 to 5, with 5 additional applications anticipated for review in Q1 2026. • Therapist Capability Expanded – 39 Perth therapists have been trained and contracted by Emyria’s Empax clinic in support of higher weekly throughput commencing Q1 next calendar year. • Perth Clinic Capacity Increasing3 – Third treatment room at Perth Clinic now operational; with fourth room approvals granted this week ahead of Q1 2026 operationalisation. • Smooth Start to Brisbane Clinic Activity – First 3 patients nearing end of Active Treatment ahead of further patient treatments in the new year. ASX RELEASE. Emyria ASX Announcement | 11 December 2025 2 Clinical Capacity Increasing A third Perth Clinic treatment room is now operational, with a fourth undergoing minor fit out works following licensing and regulatory unit site approvals. Slated to be operational in early Q1 2026, the expansion to four rooms will increase weekly treatment capacity in 2026 and support larger patient cohorts. Capital-Light National Rollout Model Perth continues to demonstrate Emyria’s ability to scale efficiently, deliver high-volume supervised care, and respond to rising payer-funded demand. Leveraging private-hospital infrastructure is not only capital efficient but also shortens commissioning timelines, expediting the forward operating outlook. The emergence of new funders, like DVA, also supports increased utilisation of established community practices. With strengthened infrastructure and resourcing, expanded reimbursed pathways and a highly trained specialist clinical team, Perth reflects the operating blueprint for rapid East Coast activation. Brisbane Clinic Update Emyria’s Brisbane Empax clinic4 is nearing completion of active treatment for its first three reimbursed patients. This marks successful onboarding of our new Brisbane-based clinical team and gives further validity to Emyria’s robust clinician recruitment and training model, clinical oversight, and workflow protocol stability ahead of a build-up to steady state patient numbers during the course of CY26. Emyria Executive Chairman, Greg Hutchinson, commented: “Our Perth clinics are now on the path expected of a mature and scalable network. Approvals are rising, our therapist cohort has strengthened, and forward bookings provide clear visibility of our patient pipeline well into 2026. With growing referrals, increasing capacity and validated clinical processes, Perth represents a template for national expansion. Emyria is well positioned to activate Empax clinics across the East Coast and deliver significant clinical and operational growth throughout 2026.” References: 1. Refer to 18 June ASX release 2. https://www.dva.gov.au/what-we-help-with/your-mental-wellbeing/psychedelic-assisted-psychotherapy- pap-using-mdma-or-psilocybin 3. Refer to 14 April ASX release 4. Refer to 29 July ASX release 5. Refer to 22 September ASX release 6. Refer to 15 October ASX release This release has been approved by the Board of Emyria. For further information, investment opportunities, or more about Emyria’s approach to mental health treatment, please contact: Greg Hutchinson Executive Chair 1300 436 363 | investors@emyria.com ASX RELEASE. Emyria ASX Announcement | 11 December 2025 3 CAUTIONARY NOTE ON FORWARD-LOOKING STATEMENTS Any statements in this press release about future expectations, plans and prospects for the Company, the Company’s strategy, future operations, and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company’s ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company’s ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represents the Company’s views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof. Risks associated with the use of MDMA, MDMA-inspired compounds and psilocybin All medicines carry risks and specialist prescribers, such as registered psychiatrists, are best placed to assess the suitability of a new medication against a patient’s individual circumstances and medical history before proceeding. Adverse effects of MDMA include high blood pressure, increased pulse rate, faintness, and panic attacks, and in some rare cases it can cause loss of consciousness or trigger seizures. Other side effects include involuntary jaw clenching, decreased appetite, restless legs, nausea, headache, sweating and muscle/joint stiffness. Adverse effects of psilocybin can include temporary increase in blood pressure and a raised heart rate. There may be some risk of psychosis in predisposed individuals. The effects of MDMA and psilocybin are unlikely at low doses in the treatment regimens used in psychedelic-assisted psychotherapy while appropriately managed in a controlled environment with direct medical supervision. The risk profile of the MDMA inspired compounds is currently unknown. The availability of these products is subject to the safety and efficacy of the products being tested through clinical trials. Emyria makes no representations or warranties as to the safety or efficacy of the products or the products’ ability (or the ability of its key compounds) to be used in the treatment of indications such as PTSD. There are currently no approved products containing MDMA, psilocybin or MDMA inspired compounds that the TGA has evaluated for quality, safety and efficacy. Emyria Limited develops and delivers new treatments for mental health and select neurological conditions through an integrated model of direct clinical services and treatment development: Emyria Healthcare: Evidence-based treatment for patients not finding relief from conventional care while also helping evaluate emerging new therapies like assisted therapy for PTSD and assisted therapy for treatment-resistant depression. Emyria Data: Robust and ethically sourced Real-World Data gathered with patients to improve Emyria’s unique therapy and drug development programs. Emyria’s Pipeline: New psychedelic-assisted therapies and drug treatments for mental health and select neurological diseases. EMYRIA’S INTERACTIVE INVESTOR HUB Investorhub.emyria.com Interact with Emyria’s announcements and updates by asking questions and comments, which our team can respond to where possible. generates informs